Opthea Q&A Sep 2024 Update, page-9

Thanks for comprehensive background on OPT. I scanned through info see Q E7 is about market impact of trial success but saw no mention of the elephant sitting on the balance sheet if trial is succesful - the $us170m funding by Launch Therapeutics. Note 27 on balance sheet explains the the repayment of this debt in event of trial success.
Note 27: As of June 30, 2024, the development financing liability was classified as a long-term liability, as the Group expects the related
repayments of $680 million (four multiples of the funding received), plus $51 million relating to withholding tax obligations to
take place between 2027 and 2032 for purposes of the model used to calculate its carrying value. The Group is liable for the
withholding tax obligations and as a result, this obligation forms part of the financial liability. The imputed interest rate on the
unamortized portion of the development financing liability was approximately 23%.

Current share price 58.5c gives mcap $A683m. Total repayment of the debt by 2032 from above will be $us680m + $us51m = $731m/0.68 = $A1075m. Dont know how OPT will fund the debt repayment (maybe combination of cap raises, debt, and sale of technology) or how all this is going to impact share price. Any thoughts?